- Telehealth Visits
Sabine Mueller, MD, PhD
Pediatric Hematology-Oncology (Neuro-Oncology) • Pediatric Neurology- Telehealth Visits
Sabine Mueller, MD, PhD
Pediatric Hematology-Oncology (Neuro-Oncology) • Pediatric Neurology- Telehealth Visits
On this page
About me
Dr. Sabine Mueller is a pediatric neuro-oncologist who specializes in caring for children with brain tumors and related genetic syndromes. Before completing medical school, she worked as a scientist, director of genomics and project leader for a brain tumor program at AGY Therapeutics, a biotechnology company in South San Francisco.
In her research, Mueller studies treatments for children with brain tumors, looking especially at improving long-term cognitive outcomes.
Mueller earned her medical degree at the Universität Hamburg Faculty of Medicine and earned a doctorate in biochemistry and molecular biology in collaboration with AGY. After a residency in pediatrics at Massachusetts General Hospital, she completed a fellowship in pediatric oncology at UCSF.
Education
Board Certification
- Pediatrics, American Board of Pediatrics
- Neurology - Child Neurology, American Board of Psychiatry and Neurology
Fellowship
- Neuro-Oncology, Univ of CA San Francisco
- Child Neurology, UCSF School of Medicine -GME
Residency
- Pediatrics, Massachusetts General Hospital
Internship
- Pediatrics, Massachusetts General Hospital
School
- MD, Universitat Hamburg
Academic Title
- Professor
Care Keywords
Services
- Pediatric Hematology-Oncology (Neuro-Oncology)
- Pediatric Neurology
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.